Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 1
2012 2
2013 3
2014 2
2015 1
2018 1
2019 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.
Leboulleux S, Do Cao C, Zerdoud S, Attard M, Bournaud C, Lacroix L, Benisvy D, Taïeb D, Bardet S, Terroir-Cassou-Mounat M, Anizan N, Bouvier-Morel E, Lamartina L, Lion G, Betrian S, Sajous C, Schiazza A, Garcia ME, Ciappuccini R, Schlumberger M, Al Ghuzlan A, Godbert Y, Borget I. Leboulleux S, et al. Clin Cancer Res. 2023 Jul 5;29(13):2401-2409. doi: 10.1158/1078-0432.CCR-23-0046. Clin Cancer Res. 2023. PMID: 37074727 Clinical Trial.
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.
Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A. Mallick U, et al. N Engl J Med. 2012 May 3;366(18):1674-85. doi: 10.1056/NEJMoa1109589. N Engl J Med. 2012. PMID: 22551128 Free article. Clinical Trial.
All 95% confidence intervals for the differences were within 10 percentage points, indicating noninferiority. Similar results were found for low-dose radioiodine plus thyrotropin alfa (84.3%) versus high-dose radioiodine plus thyroid hormone withdrawal (87.6%) or hi …
All 95% confidence intervals for the differences were within 10 percentage points, indicating noninferiority. Similar results were found for …
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Domínguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA. Ho AL, et al. N Engl J Med. 2013 Feb 14;368(7):623-32. doi: 10.1056/NEJMoa1209288. N Engl J Med. 2013. PMID: 23406027 Free PMC article. Clinical Trial.
METHODS: We conducted a study to determine whether the MAPK kinase (MEK) 1 and MEK2 inhibitor selumetinib (AZD6244, ARRY-142886) could reverse refractoriness to radioiodine in patients with metastatic thyroid cancer. After stimulation with thyrotropin alfa, dosimetr …
METHODS: We conducted a study to determine whether the MAPK kinase (MEK) 1 and MEK2 inhibitor selumetinib (AZD6244, ARRY-142886) could rever …
Novel recombinant human thyroid-stimulating hormone in aiding postoperative assessment of patients with differentiated thyroid cancer-phase I/II study.
Lin YS, Yang H, Li XY, Wu LQ, Xu JG, Yang AM, Gao ZR, Ding Y, Zhang YQ, Chen K, Mu ZZ, Jia JM, Niu N, Sun D, Zhang X, Zhang SQ, Geng QQ, Zhang YJ, Chen FN, He BX. Lin YS, et al. Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4171-4181. doi: 10.1007/s00259-022-05865-y. Epub 2022 Jul 4. Eur J Nucl Med Mol Imaging. 2022. PMID: 35781600 Clinical Trial.
Peginterferon Lambda-1a Is Associated with a Low Incidence of Autoimmune Thyroid Disease in Chronic Hepatitis C.
Fredlund P, Hillson J, Gray T, Shemanski L, Dimitrova D, Srinivasan S. Fredlund P, et al. J Interferon Cytokine Res. 2015 Nov;35(11):841-3. doi: 10.1089/jir.2014.0233. Epub 2015 Sep 16. J Interferon Cytokine Res. 2015. PMID: 26376344 Clinical Trial.
Peginterferon alfa (alfa) increases the risk of autoimmune disease. Peginterferon lambda-1a (Lambda) acts through a receptor with a more liver-specific distribution compared to the alfa receptor. ...Most Lambda recipients with abnormal TSH had levels below th …
Peginterferon alfa (alfa) increases the risk of autoimmune disease. Peginterferon lambda-1a (Lambda) acts through a receptor w …
Patterns of interferon-alpha-induced thyroid dysfunction vary with ethnicity, sex, smoking status, and pretreatment thyrotropin in an international cohort of patients treated for hepatitis C.
Mammen JS, Ghazarian SR, Rosen A, Ladenson PW. Mammen JS, et al. Thyroid. 2013 Sep;23(9):1151-8. doi: 10.1089/thy.2012.0565. Epub 2013 Aug 3. Thyroid. 2013. PMID: 23517287 Free PMC article. Clinical Trial.
METHODS: We studied 869 euthyroid patients from the ACHIEVE 2/3 trial, a randomized international clinical trial comparing pegylated-IFNalpha2a weekly or albumin-IFNalpha2b every 2 weeks for up to 24 weeks in patients with hepatitis C, genotype 2 or 3, from 136 centers. The study …
METHODS: We studied 869 euthyroid patients from the ACHIEVE 2/3 trial, a randomized international clinical trial comparing pegylated-IFNalph …
Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
Dehbi HM, Mallick U, Wadsley J, Newbold K, Harmer C, Hackshaw A. Dehbi HM, et al. Lancet Diabetes Endocrinol. 2019 Jan;7(1):44-51. doi: 10.1016/S2213-8587(18)30306-1. Epub 2018 Nov 27. Lancet Diabetes Endocrinol. 2019. PMID: 30501974 Free PMC article. Clinical Trial.
14 results